RATIONALE: The lack of consistent associations between clinical outcomes and microbiological responses to therapy for some infectious diseases has raised questions about the adequacy of microbiological endpoints for tuberculosis treatment trials. OBJECTIVES: To evaluate the association between symptoms and microbiological response to tuberculosis treatment. METHODS: We performed a retrospective analysis of four clinical trials in which participants had culture-positive tuberculosis, standardized symptom assessment, and follow-up mycobacterial cultures. Two trials (studies 22 and 23) followed participants to identify recurrent tuberculosis; participants in studies 27 and 28 were only followed to treatment completion. MEASUREMENTS AND MAIN RESULTS: This analysis included 1,978 participants; 39 (2.0%) had culture-confirmed treatment failure, and 75 (3.9%) had culture-confirmed recurrence. Productive cough was associated with indices of increased mycobacterial burden at diagnosis (acid-fast smear grade, severity of radiographic abnormalities). Fever and sweats improved rapidly with treatment, whereas productive cough decreased more slowly and was present in 20% of visits after treatment completion. During treatment, study participants with productive cough more often had concurrent culture positivity compared with those without productive cough (studies 22 and 23: adjusted odds ratio, 1.80; 95% confidence interval [CI], 1.33-2.44). Finally, symptoms during the latter part of treatment and follow-up were associated with culture-confirmed treatment failure and recurrence in studies 22 and 23 (for cough: adjusted hazard ratio, 2.07; 95% CI, 1.23-3.49; for fever: adjusted hazard ratio, 5.05; 95% CI, 2.76-9.19). CONCLUSIONS: There are consistent relationships between symptoms and microbiological indices of tuberculosis, including measures of mycobacterial burden at baseline, culture positivity during treatment, and time to culture-confirmed treatment failure and recurrence.
RATIONALE: The lack of consistent associations between clinical outcomes and microbiological responses to therapy for some infectious diseases has raised questions about the adequacy of microbiological endpoints for tuberculosis treatment trials. OBJECTIVES: To evaluate the association between symptoms and microbiological response to tuberculosis treatment. METHODS: We performed a retrospective analysis of four clinical trials in which participants had culture-positive tuberculosis, standardized symptom assessment, and follow-up mycobacterial cultures. Two trials (studies 22 and 23) followed participants to identify recurrent tuberculosis; participants in studies 27 and 28 were only followed to treatment completion. MEASUREMENTS AND MAIN RESULTS: This analysis included 1,978 participants; 39 (2.0%) had culture-confirmed treatment failure, and 75 (3.9%) had culture-confirmed recurrence. Productive cough was associated with indices of increased mycobacterial burden at diagnosis (acid-fast smear grade, severity of radiographic abnormalities). Fever and sweats improved rapidly with treatment, whereas productive cough decreased more slowly and was present in 20% of visits after treatment completion. During treatment, study participants with productive cough more often had concurrent culture positivity compared with those without productive cough (studies 22 and 23: adjusted odds ratio, 1.80; 95% confidence interval [CI], 1.33-2.44). Finally, symptoms during the latter part of treatment and follow-up were associated with culture-confirmed treatment failure and recurrence in studies 22 and 23 (for cough: adjusted hazard ratio, 2.07; 95% CI, 1.23-3.49; for fever: adjusted hazard ratio, 5.05; 95% CI, 2.76-9.19). CONCLUSIONS: There are consistent relationships between symptoms and microbiological indices of tuberculosis, including measures of mycobacterial burden at baseline, culture positivity during treatment, and time to culture-confirmed treatment failure and recurrence.
Authors: William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-05-04 Impact factor: 21.405
Authors: Robert M Jasmer; Lorna Bozeman; Kevin Schwartzman; M Donald Cave; Jussi J Saukkonen; Beverly Metchock; Awal Khan; William J Burman Journal: Am J Respir Crit Care Med Date: 2004-10-11 Impact factor: 21.405
Authors: Susan E Dorman; John L Johnson; Stefan Goldberg; Grace Muzanye; Nesri Padayatchi; Lorna Bozeman; Charles M Heilig; John Bernardo; Shurjeel Choudhri; Jacques H Grosset; Elizabeth Guy; Priya Guyadeen; Maria Corazon Leus; Gina Maltas; Dick Menzies; Eric L Nuermberger; Margarita Villarino; Andrew Vernon; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2009-04-30 Impact factor: 21.405
Authors: Thaddeus L Miller; Scott J N McNabb; Peter Hilsenrath; Jotam Pasipanodya; Stephen E Weis Journal: PLoS One Date: 2009-04-08 Impact factor: 3.240
Authors: David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; Julie V Philley; D Rebecca Prevots; Christopher Gaston; Kenneth N Olivier; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2015-09-15 Impact factor: 21.405
Authors: Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai Journal: Lancet Infect Dis Date: 2020-05-05 Impact factor: 25.071
Authors: A Singanayagam; K Manalan; D W Connell; J D Chalmers; S Sridhar; A I Ritchie; A Lalvani; M Wickremasinghe; O M Kon Journal: Int J Tuberc Lung Dis Date: 2016-12 Impact factor: 2.373
Authors: Alvaro Proaño; Marjory A Bravard; José W López; Gwenyth O Lee; David Bui; Sumona Datta; Germán Comina; Mirko Zimic; Jorge Coronel; Luz Caviedes; José L Cabrera; Antonio Salas; Eduardo Ticona; Nancy M Vu; Daniela E Kirwan; Maria-Cristina I Loader; Jon S Friedland; David A J Moore; Carlton A Evans; Brian H Tracey; Robert H Gilman Journal: Clin Infect Dis Date: 2017-05-01 Impact factor: 9.079
Authors: Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo Journal: Eur Respir J Date: 2014-03-23 Impact factor: 16.671
Authors: S E Murthy; F Chatterjee; A Crook; R Dawson; C Mendel; M E Murphy; S R Murray; A J Nunn; P P J Phillips; Kasha P Singh; T D McHugh; S H Gillespie Journal: BMC Med Date: 2018-05-21 Impact factor: 8.775